We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostic Eye Scan Technique Developed for Multiple Sclerosis

By Biotechdaily staff writers
Posted on 12 Nov 2007
A five-minute eye exam might prove to be an inexpensive and effective way to measure and track the debilitating neurologic disease multiple sclerosis (MS), potentially complementing costly magnetic resonance imaging (MRI) to detect brain shrinkage--a characteristic of the disease's progression. More...


A Johns Hopkins University- (Baltimore, MD, USA)-based study of a group of 40 MS patients used a process called optical coherence tomography (OCT) to scan the layers of nerve fibers of the retina in the back of the eye, which comprise the optic nerve. The process, which uses a desktop device similar to a slit-lamp, is simple and painless. The retinal nerve fiber layer is the one area of the brain where nerve cells are not covered with the fat and protein sheathing called myelin, making this assessment specific for nerve damage as opposed to brain MRI changes, which reflect a variety of different types of tissue processes in the brain.

Results of the scans were calibrated using accepted norms for retinal fiber thickness and then compared to an MRI of each of the patient's brains--also calibrated using accepted norms. Investigators found a correlation coefficient of 0.46, after accounting for age differences. Correlation coefficients represent how closely two variables are related--in this case MRI of the brain and OCT scans. In a subset of patients with relapsing remitting MS, the most common form of the disease, the correlation coefficient jumped to 0.69, suggesting an even stronger association between the retinal measurement and brain atrophy.

"This is an encouraging result,” said Johns Hopkins neurologist Peter Calabresi, M.D., lead author of the study, which appears in the October 2007 issue of the journal Neurology. "MRI is an imperfect tool that measures the result of many types of tissue loss rather than specifically nerve damage itself. With OCT we can see exactly how healthy these nerves are, potentially in advance of other symptoms.”

In addition, according to Dr. Calabresi, OCT scans take about one-tenth as long and cost one-tenth as much as an MRI scan, which means they are faster and less expensive to use in studies that monitor the effectiveness of new treatments for MS.

MRI of the brain, which can measure total volume, has long been the primary tool used to monitor MS. But MRI scanning, aside from being expensive and uncomfortable, is often misleading since brain inflammation--also a symptom of the disease--can distort brain volume readings. Furthermore, the brain begins shrinking relatively late in the progression of the disease, so MRI is not as effective at detecting the disease in its early stages when treatments are most effective. OCT scans look directly at the thickness, and therefore, health, of the optic nerve, which is affected early on in the disease, frequently before the patient suffers permanent brain damage.

In the study, researchers recruited 40 patients from the Johns Hopkins MS clinic. Twenty had relapsing remitting MS, 15 had secondary progressive MS, and five had primary progressive MS. Researchers also recruited 15 healthy control patients free from ophthalmologic or neurologic disease as a comparison group.


Related Links:
Johns Hopkins University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.